Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 639 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR How to Get More Support From Your Oncology Pharmacist During Cancer February 24, 2021 How to Cope With Waiting Periods During Cancer: An Expert Perspective June 1, 2023 A Systematic Analysis of the Global Burden of Disease from 2010... April 20, 2022 After Struggling With Chronic Illnesses Most of Her Life, This Author... June 21, 2021 Load more HOT NEWS How Breast Cancer Risk Assessment Tools Work Are Cancer Patients Getting the Opioids They Need to Control Pain? 41-Year-Old Wrinkled Woman Who Ages 8 Times Faster Than Normal Is... President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All...
